Bactiguard coated Foleys show significant reduction in symptomatic urinary tract infections

This non-randomized before-after cohort study included seven acute care hospitals in the United States. The hospitals had previously used standard catheters and then switched to Bactiguard-coated Foley catheters (Bardex I.C). In total, 853 patients wre included in the study, with 453 and 400 patients in the standard- and the coated Foley catheter group, respectively.

In this study, both a clinical definition of symptomatic CAUTI and the revised US Center of Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions of CAUTI were used. The revised CDC definition excludes asymptomatic bacteriuri and includes only symptomatic CAUTIs.

The results of the study show that the use of Bactiguard coated Foley catheters is associated with a significant reduction in CAUTI rates. A 47 percent relative reduction was found using both CDC and clinically defined CAUTI definitions, and a 58 percent relative reduction occurred when only CDC definitions were considered. Furthermore, a 60 percent relative reduction of antibiotic use was recorded for patients using Bactiguard coated Foley catheters.

“This is an important study, as it confirms that the use of Bactiguard coated Foleys can significantly reduce both symptomatic urinary tract infections and the use of antibiotics. This is very encouraging given the rapidly increasing problem of healthcare associated infections and antimicrobial resistance world wide,” says Johan Rugfelt, CEO of Bactiguard.

*Lederer et al. J Wound Ostomy Continence Nurs. 2014 Jun 11.
Multicenter Cohort Study to Assess the Impact of a Silver-Alloy and Hydrogel-Coated Urinary Catheter on Symptomatic Catheter-Associated Urinary Tract Infections.

Link to article in PubMed:
http://www.ncbi.nlm.nih.gov/pubmed/24922561